CORDIS
EU research results

CORDIS

English EN
Capture and enrichment of emerging pathogens for multiple and ultra-sensitive diagnostic

Capture and enrichment of emerging pathogens for multiple and ultra-sensitive diagnostic

Objective

In the 1970's WHO proclaimed that eradication of smallpox should be attempted. This goal has been achieved 1979. There is now consensus that list of newly emerging or re-emerging pathogens is continuously growing. During the last decades pathogens such as Marburg, Ebola, Hepatitis-C and Hantavirus, HIV and more recently, SARS coronavirus have emerged. Today the risk of a new influenza pandemic again highlights the global threat of infectious diseases. In addition, the possibility of bioterrorist attacks using highly pathogenic viruses and bacteria can not be ignored. Furthermore, the requirements for sensitivity and specifity of diagnostics have increased. A major obstacle for the detection of pathogens in clinical or environmental samples are false negative results, e.g. for HCV "occult infections". This is mainly due to the lack of a rapid and reliable pathogen concentration methodology, and the inability of most of the currently used technologies to eliminate or neutralize interfering "natural inhibitors" present in samples. The aim of this research program is to exploit the "non-self" recognition and binding properties of human apolipoprotein H (ApoH). ApoH binds and captures pathogens enabling their concentration from different biological samples. Magnetic beads coated with ApoH recombinant protein can be efficiently used as a pretreatment step to greatly improve the detection threshold and thereby increasing the sensitivity for diagnosis of emerging pathogens, regardless of the molecular techniques used for their diagnosis. The project will focus on viruses and bacteria from clinical and environmental samples including those that could be used in bioterrorism. In addition to the incorporation of ApoH into regular molecular techniques for pathogen detection, mini-array chips will be developed for multiple and ultra-sensitive pathogen diagnosis.'

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ROBERT KOCH-INSTITUT

Address

Nordufer 20
Berlin

Germany

Administrative Contact

Heinz ELLERBROK (Dr)

Participants (8)

Sort alphabetically

Expand all

IMMUNOCLIN LIMITED

United Kingdom

APOH-TECHNOLOGIES

France

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

Chile

EBIOCHIP SYSTEMS GMBH

Germany

SARL SKULD-TECH

France

FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

GENEXPRESS GESELLSCHAFT FÜR PROTEINDESIGN GMBH

Germany

INSTITUT DE RECHERCHES POUR LE DÉVELOPPEMENT

France

Project information

Grant agreement ID: 37560

  • Start date

    1 November 2006

  • End date

    30 April 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 3 417 323

  • EU contribution

    € 2 004 952

Coordinated by:

ROBERT KOCH-INSTITUT

Germany